Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

This combination study is designed to evaluate the safety, PK, PD and efficacy against DUPIXENT in patients with moderate-to-severe AD, with readout expected in the second half of 2026.

APG777 aims to reduce injection frequency and improve efficacy ... PD and efficacy against DUPIXENT in patients with moderate-to-severe AD, with readout expected in the second half of 2026.

Medicare covers medically necessary treatment for eczema. This includes medicated creams and pills, dupilumab (Dupixent) injections, and phototherapy. Original Medicare with a Part D plan or an ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising ... formulation requiring less frequent injections. Following FDA approval in August ...